Clincal efficacy of paclitaxel combined with three-dimensional conformal radiotherapy for locally advanced non-small cell lung cancer in the elderly
- VernacularTitle:紫杉醇单药联合三维适形放疗同步治疗老年晚期非小细胞肺癌的临床疗效观察
- Author:
Yongguang CAI
1
;
Sixian CHEN
;
Yuanyuan LI
Author Information
1. 广东省农垦中心医院肿瘤内科化疗五区
- Keywords:
Paclitaxel;
Three-dimensional conformal radiotherapy;
NSCLC;
Elderly
- From:
China Modern Doctor
2015;(11):65-68
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of paclitaxel combined with three-dimensional conformal ra-diotherapy(3DCRT) for advanced non-small cell lung cancer(NSCLC) in the elderly. Methods From June 2011 to June 2013, 51 elderly patients with NSCLC were randomly divided into chemoradiotherapy group (n=26) and chemotherapy group(n=25). All patients were treated with weekly 60 mg/m2 of paclitaxel intravenously for 3 weeks, and patients in the chemoradiotherapy group were also treated with three-dimensional conformal radiation (1.8~2.0 Gy per fraction, 5 times per week, total dose of 60~66 Gy). The clinical efficacy and adverse reactions were compared between two groups. Re-sults In chemoradiotherapy group, the response rate was 84.6% and the overall efficiency rate was 96.2%, which were higher than 60.0% and 84.0% in chemotherapy group (P<0.05). In chemoradiotherapy group, the one year survival rate was 79.2%, which was higher than 61.5% in chemotherapy group (P<0.05), so did one year progression free survival rates (67.4% vs 40.0%)(P<0.05). The main side effects were gastrointestinal toxicity, radiation esophagitis and bone-marrow suppression. Conclusion Paclitaxel combined with three-dimensional conformal radiotherapy for advanced NSCLC in the elderly are safe and effective, the toxicity is tolerable.
